Some studies showed that gefitinib can cause complete and long-lasting inhibition of EGFR phosphorylation, which depends on sequestration of inactive drug–receptor complexes in breast and ovarian carcinomas [13, 27]. Here, EGFR is linked to ovarian carcinoma.